Vetstoria vs Bristol Myers Squibb
Side-by-side comparison of AI visibility scores, market position, and capabilities
Veterinary Online Appointment Booking Platform
Real-time online appointment booking platform for veterinary practices; Dublin Ireland; raised $8M+; integrates with ezyVet, Provet Cloud, Cornerstone, and Avimark to synchronize 24/7 online bookings with clinic PIMS;
About
Vetstoria is a real-time online appointment booking platform built specifically for veterinary practices, enabling pet owners to book appointments online 24/7 through a clinic's website without phone calls, while giving veterinary teams full control over appointment types, availability, and booking rules. Founded in 2016 and headquartered in Dublin, Ireland, Vetstoria has raised approximately $8 million and grown to serve thousands of veterinary practices globally in Europe, the US, Australia, and Asia, integrating with leading practice management systems to synchronize appointments in real time.\n\nVetstoria's booking platform connects directly to a clinic's veterinary information management system — including ezyVet, Provet Cloud, Cornerstone, Avimark, and others — so bookings made online appear immediately in the practice schedule without staff intervention, and availability shown to clients accurately reflects real-time slot availability. Clinics control which appointment types are bookable online, can set deposit requirements for high-demand slots, and can restrict booking access to existing clients only. Analytics provide data on booking conversion rates, booking source (website, Google, social), and time-of-day patterns.\n\nVetstoria competes with PetDesk, Vetster, and general appointment booking platforms adapted from human healthcare in the veterinary booking space. Its deep PIMS integrations and purpose-built veterinary rules engine — which can handle species-specific booking logic, new patient workflows, and emergency appointment routing — differentiate it from generic online booking tools. The platform helps veterinary practices capture after-hours booking demand, reduce front-desk call volume, and improve the client experience for digitally-oriented pet owners.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
About
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.